RGD Reference Report - Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.

Authors: Kuo, I-Ying  Chang, Jia-Ming  Jiang, Shih-Sheng  Chen, Chung-Hsin  Chang, I-Shou  Sheu, Bor-Shyang  Lu, Pei-Jung  Chang, Wei-Lun  Lai, Wu-Wei  Wang, Yi-Ching 
Citation: Kuo IY, etal., Int J Med Sci. 2014 May 30;11(8):779-87. doi: 10.7150/ijms.7405. eCollection 2014.
RGD ID: 153323298
Pubmed: PMID:24936140   (View Abstract at PubMed)
PMCID: PMC4057483   (View Article at PubMed Central)
DOI: DOI:10.7150/ijms.7405   (Journal Full-text)


BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis. We aimed to identify a panel of CpG methylation biomarkers for prognosis prediction of ESCC patients.
METHODS: Illumina's GoldenGate methylation array, supervised principal components, Kaplan-Meier survival analyses and Cox regression model were conducted on dissected tumor tissues from a training cohort of 40 ESCC patients to identify potential CpG methylation biomarkers. Pyrosequencing quantitative methylation assay were performed to validate prognostic CpG methylation biomarkers in 61 ESCC patients. The correlation between DNA methylation and RNA expression of a validated marker, SOX17, was examined in a validation cohort of 61 ESCC patients.
RESULTS: We identified a panel of nine CpG methylation probes located at promoter or exon1 region of eight genes including DDIT3, FES, FLT3, NTRK3, SEPT5, SEPT9, SOX1, and SOX17, for prognosis prediction in ESCC patients. Risk score calculated using the eight-gene panel statistically predicted poor outcome for patients with high risk score. These eight-gene also showed a significantly higher methylation level in tumor tissues than their corresponding normal samples in all patients analyzed. In addition, we also detected an inverse correlation between CpG hypermethylation and the mRNA expression level of SOX17 gene in ESCC patients, indicating that DNA hypermethylation was responsible for decreased expression of SOX17.
CONCLUSIONS: This study established a proof-of-concept CpG methylation biomarker panel for ESCC prognosis that can be further validated by multiple cohort studies. Functional characterization of the eight prognostic methylation genes in our biomarker panel could help to dissect the mechanism of ESCC tumorigenesis.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
FESHumanesophagus squamous cell carcinoma exacerbatesIDA DNA:hypermethylation: (human)RGD 
FesMouseesophagus squamous cell carcinoma exacerbatesISOFES (Homo sapiens)DNA:hypermethylation: (human)RGD 
FesRatesophagus squamous cell carcinoma exacerbatesISOFES (Homo sapiens)DNA:hypermethylation: (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Fes  (FES proto-oncogene, tyrosine kinase)

Genes (Mus musculus)
Fes  (feline sarcoma oncogene)

Genes (Homo sapiens)
FES  (FES proto-oncogene, tyrosine kinase)


Additional Information